Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease.
Crohn’s disease
Maintenance
On-body injector
Risankizumab
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
23
01
2023
accepted:
20
02
2023
medline:
17
5
2023
pubmed:
15
3
2023
entrez:
14
3
2023
Statut:
ppublish
Résumé
In patients with moderate to severe Crohn's disease (CD), intravenous induction and subcutaneous maintenance dosing with risankizumab was efficacious and well tolerated. Long-term management of CD via self-administration of risankizumab using an on-body injector (OBI) may improve treatment adherence through convenience and ease of use. Within the FORTIFY maintenance study, 46 patients from the United States (US) sites participated in an open-label extension Substudy and received 180 mg or 360 mg risankizumab delivered subcutaneously via OBI [360 mg (2.4 mL, 150 mg/mL) or 180 mg (1.2 mL, 150 mg/mL)]. At the Week 0 visit, patients were trained (pre-injection) by site staff, using Instructions for Use (IFU) and a training video, to self-administer risankizumab at Weeks 0 (on site), 8 (at home), and 16 (on site). Key objectives of the Substudy 4 were to assess OBI usability (observer rating of successful self-administration), hazard-free self-injection at Weeks 0 and 16, and patient rating of acceptability using the Self-Injection Assessment Questionnaire (SIAQ) at Weeks 0, 8, and 16. Additionally, the proportion of patients in clinical remission (CD Activity Index < 150) was collected at Weeks 0 and 16. All patients successfully self-administered risankizumab via OBI, including two patients who successfully self-administered with a second OBI (i.e., required two injection attempts). Acceptability of self-injection was high. Two patients (n = 2) experienced a use-related hazard. Stable clinical remission was observed with both risankizumab doses. Two patients experienced injection site reactions; neither was related to the OBI per investigator's assessment. Two device-related adverse events related to topical adhesive reactions were reported, both mild and resolved. No new safety risks were observed. The efficacy and safety of maintenance risankizumab delivered via OBI and OBI usability support the use of this device in patients with moderate to severe CD. ClinicalTrials.gov identifiers NCT03105102 (FORTIFY).
Identifiants
pubmed: 36917429
doi: 10.1007/s12325-023-02477-2
pii: 10.1007/s12325-023-02477-2
pmc: PMC10011765
doi:
Substances chimiques
Antibodies, Monoclonal
0
risankizumab
90ZX3Q3FR7
Banques de données
ClinicalTrials.gov
['NCT03105102']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2311-2325Informations de copyright
© 2023. The Author(s).
Références
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.
doi: 10.1056/NEJMra050100
pubmed: 16079372
Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114(1):39–43.
doi: 10.1016/S0002-9343(02)01383-9
pubmed: 12543288
Khan N, Abbas AM, Bazzano LA, Koleva YN, Krousel-Wood M. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther. 2012;36(8):755–64.
doi: 10.1111/apt.12013
pubmed: 22882428
van der Have M, Oldenburg B, Kaptein AA, Jansen JM, Scheffer RCH, van Tuyl BA, et al. Non-adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study. ECCOJC. 2016;10(5):549–55.
doi: 10.1093/ecco-jcc/jjw002
Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53(4):1020–4.
doi: 10.1007/s10620-007-9968-0
pubmed: 17934828
Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol. 2008;33(8):867–74.
doi: 10.1093/jpepsy/jsn022
pubmed: 18337262
pmcid: 2493513
Perry J, Chen A, Kariyawasam V, Collins G, Choong C, Teh WL, et al. Medication non-adherence in inflammatory bowel diseases is associated with disability. Intest Res. 2018;16(4):571–8.
doi: 10.5217/ir.2018.00033
pubmed: 30301333
pmcid: 6223449
Chan W, Chen A, Tiao D, Selinger C, Leong R. Medication adherence in inflammatory bowel disease. Intest Res. 2017;15(4):434.
doi: 10.5217/ir.2017.15.4.434
pubmed: 29142511
pmcid: 5683974
D’Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015–30.
doi: 10.1016/S0140-6736(22)00467-6
pubmed: 35644154
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031–46.
doi: 10.1016/S0140-6736(22)00466-4
pubmed: 35644155
Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9(1):2.
doi: 10.1186/1477-7525-9-2
pubmed: 21232106
pmcid: 3027089
Suleiman AA, Goebel A, Bhatnagar S, D’Cunha R, Liu W, Pang Y. Population pharmacokinetic and exposure–response analyses for efficacy and safety of risankizumab in patients with active Crohn’s disease. Clin Pharm Ther. 2023:cpt.2831.
Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649.
doi: 10.1001/jamadermatol.2020.0723
pubmed: 32267471